Literature DB >> 21139807

ACE variants and association with brain Aβ levels in Alzheimer's disease.

J Scott Miners, Zoë van Helmond, Merryn Raiker, Seth Love, Patrick G Kehoe.   

Abstract

ACE is a candidate gene for Alzheimer's disease (AD) and associations have been reported between ACE variants and plasma ACE levels, AD risk, AD age at onset of disease and cerebrospinal fluid levels of Aβ. Despite evidence that ACE can degrade Aβ, the relationships between ACE variants and the levels of different types of Aβ in the brain are not known. We have investigated the relationship between AD-associated ACE variants, for which the associations with brain activity of ACE were previously analysed, and brain homogenate levels of soluble, insoluble and oligomeric Aβ. Reported AD risk variants in the ACE indel (rs1799752) and its 'proxy' rs4343 were significantly associated with soluble Aβ level in AD only (p=0.001), as was rs1800764 but less so (p=0.014). In contrast, insoluble Aβ was associated with ACE indel and rs4343 variants in controls only (p < 0.01). No associations were found for oligomeric Aβ. These data indicate a complex relationship between ACE and Aβ that differs between AD and control brains.

Entities:  

Keywords:  ACE; Alzheimer's disease; Aβ degrading enzyme; SNP; amyloid; angiotensin; association; cerebral blood flow; hypertension; insoluble Aβ; neuropathology; soluble Aβ

Year:  2010        PMID: 21139807      PMCID: PMC2981427     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  53 in total

1.  ACE activity in CSF of patients with mild cognitive impairment and Alzheimer disease.

Authors:  M He; T Ohrui; M Maruyama; N Tomita; K Nakayama; M Higuchi; K Furukawa; H Arai
Journal:  Neurology       Date:  2006-10-10       Impact factor: 9.910

2.  Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease.

Authors:  N M Barnes; C H Cheng; B Costall; R J Naylor; T J Williams; C M Wischik
Journal:  Eur J Pharmacol       Date:  1991-08-06       Impact factor: 4.432

3.  ACE variants and risk of intracerebral hemorrhage recurrence in amyloid angiopathy.

Authors:  Sophie Domingues-Montanari; Mar Hernandez-Guillamon; Israel Fernandez-Cadenas; Maite Mendioroz; Mercè Boada; Josep Munuera; Alex Rovira; Olga Maisterra; Mireia Parés; Maria Gutierrez; José Alvarez-Sabin; Pilar Chacón; Pilar Delgado; Joan Montaner
Journal:  Neurobiol Aging       Date:  2010-04-09       Impact factor: 4.673

4.  The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide.

Authors:  Ryutaro Oba; Akira Igarashi; Makiko Kamata; Kinya Nagata; Syoichi Takano; Hachiro Nakagawa
Journal:  Eur J Neurosci       Date:  2005-02       Impact factor: 3.386

Review 5.  Hypertension, hypertension-clustering factors and Alzheimer's disease.

Authors:  Ingmar Skoog; Deborah Gustafson
Journal:  Neurol Res       Date:  2003-09       Impact factor: 2.448

Review 6.  Medical management of acute intracerebral hemorrhage.

Authors:  Craig S Anderson
Journal:  Curr Opin Crit Care       Date:  2009-04       Impact factor: 3.687

7.  Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition.

Authors:  Kun Zou; Haruyasu Yamaguchi; Hiroyasu Akatsu; Takaaki Sakamoto; Mihee Ko; Kazushige Mizoguchi; Jian-Sheng Gong; Wenxin Yu; Takayuki Yamamoto; Kenji Kosaka; Katsuhiko Yanagisawa; Makoto Michikawa
Journal:  J Neurosci       Date:  2007-08-08       Impact factor: 6.167

Review 8.  Angiotensins in Alzheimer's disease - friend or foe?

Authors:  Patrick G Kehoe; Scott Miners; Seth Love
Journal:  Trends Neurosci       Date:  2009-09-30       Impact factor: 13.837

9.  Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease.

Authors:  P G Kehoe; C Russ; S McIlory; H Williams; P Holmans; C Holmes; D Liolitsa; D Vahidassr; J Powell; B McGleenon; M Liddell; R Plomin; K Dynan; N Williams; J Neal; N J Cairns; G Wilcock; P Passmore; S Lovestone; J Williams; M J Owen
Journal:  Nat Genet       Date:  1999-01       Impact factor: 38.330

10.  Common variants of ACE contribute to variable age-at-onset of Alzheimer's disease.

Authors:  Patrick G Kehoe; Hagit Katzov; Niels Andreasen; Maragaret Gatz; Gordon K Wilcock; Nigel J Cairns; Juni Palmgren; Ulf de Faire; Anthony J Brookes; Nancy L Pedersen; Kaj Blennow; Jonathan A Prince
Journal:  Hum Genet       Date:  2004-02-17       Impact factor: 4.132

View more
  25 in total

1.  Phosphorylation of amyloid-β peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes.

Authors:  Sathish Kumar; Sandesh Singh; Désirée Hinze; Michaele Josten; Hans-Georg Sahl; Martin Siepmann; Jochen Walter
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

2.  Candidate genes for Alzheimer's disease are associated with individual differences in plasma levels of beta amyloid peptides in adults with Down syndrome.

Authors:  Nicole Schupf; Annie Lee; Naeun Park; Lam-Ha Dang; Deborah Pang; Alexander Yale; David Kyung-Taek Oh; Sharon J Krinsky-McHale; Edmund C Jenkins; José A Luchsinger; Warren B Zigman; Wayne Silverman; Benjamin Tycko; Sergey Kisselev; Lorraine Clark; Joseph H Lee
Journal:  Neurobiol Aging       Date:  2015-06-19       Impact factor: 4.673

3.  Genetic variation in MME in relation to neprilysin protein and enzyme activity, Aβ levels, and Alzheimer's disease risk.

Authors:  Scott Miners; Zoë van Helmond; Rachel Barker; Peter A Passmore; Janet A Johnston; Stephen Todd; Bernadette M McGuinness; Francesco Panza; Davide Seripa; Vincenzo Solfrizzi; Seth Love; Jonathan A Prince; Patrick G Kehoe
Journal:  Int J Mol Epidemiol Genet       Date:  2012-02-05

4.  Modulation of Renin-Angiotensin System May Slow Conversion from Mild Cognitive Impairment to Alzheimer's Disease.

Authors:  Whitney Wharton; Felicia C Goldstein; Liping Zhao; Kyle Steenland; Allan I Levey; Ihab Hajjar
Journal:  J Am Geriatr Soc       Date:  2015-09       Impact factor: 5.562

5.  Neurofibrillary Tangles and Conversion to Mild Cognitive Impairment with Certain Antihypertensives.

Authors:  Whitney Wharton; Liping Zhao; Kyle Steenland; Felicia C Goldstein; Julie A Schneider; Lisa L Barnes; Marla Gearing; Sevil Yasar
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

6.  Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer's (HEART) Trial.

Authors:  Whitney Wharton; Felicia C Goldstein; Malú G Tansey; Alexandra L Brown; Sonum D Tharwani; Danielle D Verble; Amarallys Cintron; Patrick G Kehoe
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 7.  Cerebral Hypoperfusion and the Energy Deficit in Alzheimer's Disease.

Authors:  Seth Love; J Scott Miners
Journal:  Brain Pathol       Date:  2016-09       Impact factor: 6.508

8.  Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation.

Authors:  John S K Kauwe; Matthew H Bailey; Perry G Ridge; Rachel Perry; Mark E Wadsworth; Kaitlyn L Hoyt; Lyndsay A Staley; Celeste M Karch; Oscar Harari; Carlos Cruchaga; Benjamin J Ainscough; Kelly Bales; Eve H Pickering; Sarah Bertelsen; Anne M Fagan; David M Holtzman; John C Morris; Alison M Goate
Journal:  PLoS Genet       Date:  2014-10-23       Impact factor: 5.917

9.  Synaptic protein levels altered in vascular dementia.

Authors:  Lindsey I Sinclair; Hannah M Tayler; Seth Love
Journal:  Neuropathol Appl Neurobiol       Date:  2015-04-23       Impact factor: 8.090

10.  Chronic inhibition of central Angiotensin-converting enzyme ameliorates colchicine-induced memory impairment in mice.

Authors:  Himani Awasthi; Deep Kaushal; Hefazat Husain Siddiqui
Journal:  Sci Pharm       Date:  2012-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.